Dr. PhD  

Stefanie Krampe

, Germany


Presentations

Guselkumab is the favorable initial treatment option in patients with moderate-to-severe plaque psoriasis naive to systemic treatment and is also effective after switch from FAE to guselkumab 09 October 2019 00:00 - 00:00
The 64-week safety profile of guselkumab is favorable compared to fumaric acid esters in psoriasis patients - long term safety results from the German POLARIS trial 09 October 2019 00:00 - 00:00
Guselkumab is superior compared to fumaric acid esters in improving the quality of life of systemic naive and FAE pre-treated psoriasis patients - week 56 results from the POLARIS trial 09 October 2019 00:00 - 00:00